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Background 1
A complete understanding of REDOX biology within the Sarcoplasmic/Endoplasmic 2 Reticulum (SR/ER) and any influence over cellular metabolism is lacking. Hexose-6-3 phosphate dehydrogenase (H6PDH) is the only recorded generator of NADPH (from NADP + ) 4 within this cellular compartment. This exclusivity ensures its importance to not only SR/ER 5 REDOX control and coenzyme generation for pyridine nucleotides, but also implicates it into 6 wider skeletal muscle homeostasis 1, 2 . 7
The pyridine Nicotinamide Adenine Dinucleotide (NAD + ) is a fundamental contributor to 8 cellular REDOX maintenance and energetic utilisation 3, 4 . The rate limiting nature of NAD + to 9 biochemical reactions make it fundamental to energetic metabolism including mitochondrial 10 fatty acid catabolism and ATP generation. 11
Pharmacologic augmentation of NAD + through the use of precursors such as Nicotinamide 12
Riboside (NR) has shown restorative potential in NAD + based therapies using a variety of 13 cell types and animal models with supportive human studies [5] [6] [7] [8] [9] [10] . Recent studies back this, 14
showing a loss of NAD + salvage function leads to progressive muscle degeneration and 15 boosting of the nicotinamide salvaging pathways liberates skeletal muscles from some of the 16 deleterious impacts of ageing, muscular dystrophy and high-fat diet phenotypes [10] [11] [12] [13] . The 17 phosphorylation of NR into nicotinamide mononucelotide (NMN) occurs through two 18 nicotinamide riboside kinases (NRKs) NRK1 and NRK2. In many tissues NRK1 is the 19 dominant and rate limiting source of NR phosphorylation 14 . However, in skeletal muscle 20 NRK2 is highly expressed and recent data highlights its roles within myocyte physiology 8 . 21
Biosynthetic salvage of nicotinamide mediated by NRK2 has only recently been identified as 22 having relevance to skeletal muscle biology and its function within atrophic models, ER 23 stress and REDOX dysfunction are unstudied. 24
Furthermore, maintenance of the Sarcoplasmic Reticulum (skeletal muscle only) SR/ER 25 REDOX pyridine pools and its contribution to whole cell NAD + levels is unclear. Hexose-6-26 phosphate dehydrogenase (H6PD) converts glucose 6-phosphate (G6P) to 6-27 Phosphoglucogonate (6-PG) and 6-Phosphglucogonatelactonase (6-PGL). Within the 28
Results 1
Sarco/Endoplasmic confined H6PD knockout produces muscle wide metabolic 2 alterations in Nicotinamide metabolism. The Sarcoplasmic/Endoplasmic Reticulum 3 serves as a major calcium store, driving the contractile response and contributing towards 4 REDOX homeostasis through the generation of NADPH by H6PD. Previously, studies show 5 the ablation of H6PDH in conditional skeletal muscle and whole body models provoking a 6 muscle myopathy driven by SR/ER stress and the unfolded protein response. Additionally, 7 the physiological role of H6PD upon glucocorticoid metabolism have been characterised, 8
further highlighting the importance of SR/ER REDOX to NADPH generation 15, 18 . We 9 subjected skeletal muscle extracted from WT and H6KO mice to an unbiased metabolomic 10 screen to better understand the role H6PD plays in wider muscle cell metabolism and SR/ER 11 REDOX maintenance. This unbiased metabolite profile shows significant differential 12 abundance of metabolites in the H6KO muscle (Supplementary Table 1 ). The N6,N6,N6.-13
Trimethyl-L-Lysine metabolite is a methylated derivative of the amino acid lysine, a 14 constituent of nuclear histone proteins and a precursor to carnitine and fatty acid oxidation in 15 the mitochondria. 3-Hydroxysebasicacid was also significantly elevated in the H6KO muscle, 16 a metabolite elevated in the urine of humans with peroxisomal disorders and glycogen 17 storage disease 21, 22 , signalling a defect in fatty acids synthesis and metabolic defects such 18 as medium chain acyl-CoA dehydrogenase deficiency. Cis-5-Tetradecenoylcarnitine is a 19 marker of long chain acyl-dehydrogenase (VLCAD) deficiency, alterations in metabolites 20 regulating beta oxidation are contributory to skeletal muscle myopathy 23 . There are 21 significant elevations in both the metabolite Nicotinamide Adenine Dinucleotide (NAD + ) and 22 the methylated form of NAD + , 1-methylnicotinamide. This dataset was subject to pathway 23 analysis to reveal overrepresentation of metabolites that sharing a metabolic pathway. The 24 most highly overrepresented pathways were nicotinamide and pyridine biosynthesis ( Figure  25 
1A-B). Changes in NAD
+ availability to skeletal muscle profoundly impacts downstream 26 reactions intrinsic to metabolic function and defects in NAD + homeostasis are contributory to 27 disease development [24] [25] [26] . To gain further insight NAD + generation in relation to the H6KO 28 model we conducted quantification of NAD + , NAD(H) and NAD(H)total abundance in WT and 1 H6KO skeletal muscle. These data show no significant NAD + changes of H6KO in 2 comparison to WT. NADH is significantly decreased in H6KO, however, measurement of 3 total NAD(H) levels were indifferent to WT (Figure 1E-H Figure 1G ). Real-time PCR analysis of these genes responsible for muscle NAD + 9 biosynthesis and salvage demonstrates changes in both biosynthetic and NAD + 10 phosphorylating genes ( Figure 1H ). There is significant increase in the skeletal muscle 11 restricted nicotinamide riboside kinase 2 gene (NRK2), whilst the constitutively expressed 12 NRK1 and NAMPT are unchanged. to assess mitochondrial metabolic function we subjected permeabilised skeletal muscle 10 fibres from both the Tibialis anterior (TA) and Soleus (SOL) muscle beds to high-resolution 11 respirometery, exploiting mitochondria's fatty acid oxidative capacity. Measurement of the 12 fast twitch TA muscle from H6KO mice shows a decreased ability to consume oxygen for 13 energetic metabolism in the H6KO model (Figure 2A ). This defect was also apparent in slow 14 twitch Soleus muscle from H6KO ( Figure 2B ). This suggests H6KO ablation has a 15 detrimental impact upon mitochondria and the elevations in NAD + biosynthesis measured in 16 NRK2 increased abundance are ineffectual and their impact upon mitochondrial 17 metabolism. These results show H6KO (fast and slow twitch) muscle has significantly 18 decreased ability to utilise substrates for fatty acid beta-oxidation and overall respiratory 19 capacity. To understand if these measurements are a measure of functionality and not 20 mitochondrial abundance we examined mtDNA content in both WT and H6KO muscle and 21 found them to be unchanged ( Figure 2C) . Together these data demonstrate in addition to 22 the SR/ER disturbances H6KO skeletal muscle there is a widespread inability to utilise 23 sources of energy for cellular respiration rising from occlusion in the generation of pyridine 24 nucleotide NADPH within the SR/ER. This leads to widespread physiological deficits in 25 mitochondrial function without altering mitochondrial protein levels. Total protein 26 measurement and quantification of mitochondrial respiratory complex subunits indicated no 27 change in overall abundance of ATP generating complexes ( Figure 2D ). Using a targeted 28 metabolomic analysis of acylcarnitines and other metabolites (Supplementary Figure 2) we 1 find short-chain acylcarnitines (C2, C3, C4, C5, C6 & C10:1) were differentially upregulated 2 in H6KO muscle tissue, the ratio of acetylcarnitine to free carnitine (C2:C0) was increased 3 signifying elevations in even numbered fatty acids within the H6KO. Free-carnitine was not 4 significantly different in H6KO versus WT tissue ( Figure 2E ). To gain further insight and 5 reconcile observed changes in myofibre carnitine composition and shifts in phospholipid 6 species we used real-time qPCR to examine expression of genes integral to carnitine 7 acylation, lipid mobilisation and fatty acid metabolism. H6KO tissue shows significant 8 elevations in acss2, far1, acsl2, acaa2 and scd1 ( Figure 2F but failed to achieve significance. This potentially signifies that although H6PD is the sole 26 source of NADPH in the SR/ER and despite the high abundance of SR/ER in skeletal 27 muscle it may not be a significant contributor towards total myocellular NAD(H). These data 28 demonstrate i.p NR over an acute schedule (4 days) is successful and elevating cellular 1 NAD + in both WT and H6KO metabolically challenged mice. However, NADH is only 2 augmented in the H6KO model, reflecting the enhanced NAD + biosynthetic and salvage 3 network identified in the unbiased metabolomic screen. Transcript analysis of genes integral 4 to NAD biosynthesis and salvage showed a decrease in NRK2 in WT, not shown in H6KO. 5 I.P NR was successful at increasing the expression of NMNAT1, NAMPT and NRK1 in 6 H6KO muscle, responses not measured in WT cells and may reflect shifts in the biosynthetic 7 generation of the H6KO model. Additionally, a lack of response from NRK2 in the H6KO may 8 suggest NRK2 is transcript is functioning towards physiological capacity ( Figure 3E ). 9
Measurement of transcripts regulating Acyl-CoA and lipid metabolism enzymes contributing 10 towards beta-oxidation reveals that NAD + boosting has no impact over their expression 11 were probed for the ER stress response protein CHOP and the protein folding regulators 26 ERO1a and PDI ( Figure 3K ). From these data it is evident that the acute i.p NR protocol has 27 no significant impact upon the protein expression, suggesting that benefits of NAD + boosting 28 in other cellular functions may not extend into the ER/SR of skeletal muscle. NAD + boosting 1 as a strategy to increase availability of the rate-limiting factor for the sirtuin enzyme family 2 has shown some promising outcomes. Therefore, to assess acetylation levels changes in 3 response to acute i.p NR in both WT and H6KO muscle protein lysates from these mice 4 were examined for global acetylation and acetylation of the mitochondrial enzyme IDH2. 5
These data show there was no change in acetylation status shown when compared to sham 6 controls ( Figure 3L) . 7
Ablation of NRK2 within the H6KO muscle decreases NAD + levels and is independent 8 to the H6KO skeletal muscle myopathy. 9
As boosting of NAD + did not change the mitochondrial function or ER/SR stress status of the 10 H6KO muscle we investigated the potential to perturb the H6KO induced NRK2 response. 11
With our hypothesis stating NRK2 as being a dominant muscle NAD + contributing pathway 12 crucial to whole cell pyridine levels. To challenge this we produced a double knockout 13 model, deficient in both H6PD and NRK2. As NRK2 is skeletal muscle restricted, we 14 reasoned that its ablation in the H6KO would negatively affect cellular NAD + content, 15 exacerbating the H6KO muscle myopathy phenotype. Quantification of NAD + levels revealed 16 that the Double knockout TA has significantly decreased NAD + and total NAD(H) total, 17 indicating that the ablation of NRK2 in the H6 null muscle (Figure 4A-D) . H6KO skeletal 18 muscle beds exhibit myopathy, this is reflected in the decreased muscle bed weights (Figure  19 4 E-G). Assessment of NAD biosynthesis and salvage gene expression revealed no 20 significant change in the DKO muscle compared to H6KO (NRK2 KO has no significant 21 change compared to WT mice), suggesting that ablation of skeletal muscle restricted NRK2 22 can reduce the levels of NAD(H) generated but this may not affect cellular metabolic function 23 The SR/ER located H6PD is the only know source of NADPH within this largely impermeable 6 compartment. Currently there is a gap in our understanding of how nucleotide pools 7 independent to the cytosol (a high consumer of cellular NADPH with its own maintenance 8 stores) relate to cellular pyridine homeostasis. We demonstrate that ER REDOX dysfunction 9 perturbs mitochondrial lipid metabolism and cytosolic NRK2 mediated NAD + biosynthesis 10 within skeletal muscle. The reduced bioenergetic capacity of H6KO mitochondria 11
demonstrates that SR/ER stress signals confer extensive metabolic impairment. However, 12 these direct signalling mechanism remains unresolved. 13
In contrast to H6KO conditional and global murine models that show a profound upregulation 14 of the ER stress response human cancer cell lines of breast origin transient knockdown of 15 H6PD produced a down regulation in ER stress 30 . Also reported was a reduction in migration 16 and enhanced cell adhesion, these data suggest not only that cancer cells show reliance 17 upon H6PD mediated NADPH generation for their proliferation but also that H6PD maybe a 18 novel target. Importantly, supportive of our work this study in human cancer cells also 19 demonstrated an increased mitochondrial superoxide levels, indicative of mitochondrial 20 impairment. We demonstrate the SR/ER capability to create mitochondrial dysfunction, 21 further quantifying the level of mitochondrial respirometry in H6PD defunct myofibres. 22
Supportive of this notion is the identification of H6PD as a target of PARP inhibitor 23
Rucaparib, (PARPs being NAD+ dependent enzymes) indicating current anti-cancer 24 therapeutic strategies may already be exploiting the ability of the SR/ER to impact wider cell 25 metabolism
. 26
In an attempt to exploit enhanced NAD + biosynthetic enzyme expression in the H6KO 27 skeletal muscle we delivered a saturated supply of high dose precursor, nicotinamide 28 riboside. This was successful at enhancing NAD + levels within the tissue, also it elevated 1 NADH within H6KO samples. However, there was no change over the recorded metabolic 2 features of the H6KO model with ER stress, acylation and mitochondrial fatty acid oxidation 3 unchanged. Thus physiologically the elevation in NAD + was unable to overcome the 4 negative attributes of H6PD ablation. The acute nature of the supply of NR (4 days) maybe 5 considered a limitation of the study, with this duration it is unlikely that structural aberrations 6 induced by the H6KO might be rescued. However, the acute delivery of NR did induce NAD 7 sifts recorded within skeletal muscle in addition to regulatory changes in genes important to 8 NAD + utilisation and salvage. 9
As an alternative strategy to challenge the relationship between NAD + biosynthesis and the 10 SR/ER REDOX enzyme H6PD we produced a duel-knockout model with ablated H6PD-11 NRK2. This model exhibited a level of skeletal muscle myopathy comparable to the H6KO 12 that was not exacerbated or rescued by the lack of NRK2 gene product. These data suggest 13 generation of NADPH within the SR/ER by H6PD is essential to cellular metabolic functions 14 external to the SR/ER environment. Differential NAD + homeostasis has been demonstrated 15 to be present in muscular pathologies such as muscular dystrophy and infantile onset 16
Pompe disease 32, 33 . The latter being a glycogen storage disease and reflective of the H6PD 17 glycogen storage defects 34 . Also in cardiac muscle it has been demonstrated that 18 upregulation of NRK2 occurs as a response to congestive heart failure 7 . Herein we detail a 19 similar mechanism for skeletal muscle with enhanced expression of NRK2 mRNA and 20 protein indicating that this is an adaptive response and occurs independently of NAMPT 21 activity. Attempting to delineate the NAD + biosynthetic changes introduced by H6PD showed 22 although there was significant elevations in NRK2 mediated expression its NAD + generating 23 contribution is presumably attenuated by the unchanged expression levels of the rate limiting 24 NMNAT enzymes. Furthermore, the increase of NRKs (in particular NRK2) maybe an 25 attempt to rectify the REDOX alteration within the H6PD KO SR/ER. Should this notion be 26 confirmed would support the concept of organelle sensing and exchange of nucleotides, an 27 attribute whose existence remains unclear partly due to a lack of identified transporters for 28 pyridine nucleotides. However, recent published data support the existence of mitochondrial 1 membrane transporters able to distribute pyridine nucleotides between cytosolic and 2 mitochondria, indeed the compartmentalisation of NAD + as a cellular mechanism capable of 3 regulating metabolism and their transcriptional programmes is now apparent 35 . Movement of 4 NAD + has been more specifically evaluated and the existence of a transporter able to flux 5 NAD + to and from the mitochondria has been shown, although the identification of the 6 responsible protein(s) remains unknown 36 . 7 8
Conclusion 9
Our work shows although NAD + boosting has pharmacologic utility in maintaining metabolic 10 health of skeletal muscle, the underlying REDOX status of the cell can be determinant of its 11 impact. Here we find that adaptive upregulation of the NRK pathway is unproductive, yielding 12 no increase in NAD + or NADH. Furthermore, attempts to exacerbate the H6KO model 13 defective phenotype by ablating the NRK2 gene and producing a double knockout had no 14 impact upon the skeletal muscle. This is supportive of the recent findings regarding the 15 redundant nature of the NRKs, indicating NRK1 and NAMPT adaptive actions. Additionally, 16 attempts to increase NAD + levels with acute intraperitoneal NR in the H6KO models were 17 successful but had no significant impact over the physiology with many pathways failing to 18 show a response differential from WT mice. Therefore, our work shows for the first time that 19 NAD + biochemistry and the value of NAD + boosting as a strategy is dependent upon the 20 metabolic context and REDOX stress environment within the target tissue. These being 21 previously unidentified key determinants in the potential use of NAD + precursor compounds. 22
Production of a double knockout of H6PD and NRK2 was successful at reducing total levels 23 of skeletal muscle NAD(H) suggesting the existence REDOX influence over the cytosol and 24 mitochondria that may impact metabolic functionality beyond the confined SR/ER 25 
